Drugs and Steatohepatitis

 

 Buy Article Permissions and Reprints

ABSTRACT

In addition to the usual associations with insulin resistance, type 2 diabetes, central obesity, and hypertriglyceridemia, nonalcoholic steatohepatitis (NASH) has been associated with several drugs and toxins. However, drug-induced liver disease is a relatively uncommon cause of steatohepatitis. The term drug-induced steatohepatitis is preferred when the association appears to result from a direct toxic effect of the drug on the liver. For some agents implicated as causing cirrhosis or fatty liver disorders, the association may be coincidental because NASH is a common component of the insulin resistance (or metabolic) syndrome. In other instances, corticosteroids, tamoxifen, and estrogens may precipitate NASH in predisposed persons by exacerbating insulin resistance, central obesity, diabetes, and hypertriglyceridemia, and methotrexate may worsen hepatic fibrosis in NASH. Drug-induced steatohepatitis is associated with prolonged therapy (more than 6 months) and possibly drug accumulation, which in the case of perhexiline maleate is favored by a genetic polymorphism of CYP2D6 that leads to slow perhexiline oxidation. The toxic mechanism appears to involve mitochondrial injury, which causes steatosis because of impaired β-oxidation of fatty acids, and leads to generation of reactive oxygen species and ATP depletion. Thus, drug-induced steatohepatitis may provide clues to injurious events in the more common metabolic forms of NASH. A clinical feature of some types of drug-induced steatohepatitis is progression after discontinuation of the causative agent. It follows that early recognition of hepatotoxicity is crucial to prevent the development of severer forms of liver disease and improve the clinical outcome.

REFERENCES

• 1 Ludwig J, McGill D B, Lindor K D. Review: nonalcoholic steatohepatitis.  J Gastroenterol Hepatol . 1997;  12 398-403
  CrossrefPubMedGoogle Scholar
• 2 Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients.  Am J Med . 1979;  67 811-816
  CrossrefPubMedGoogle Scholar
• 3 Angulo P, Keach J C, Batts K P. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology . 1999;  30 1356-1362
  CrossrefPubMedGoogle Scholar
• 4 Ratziu V, Giral P, Charlotte F. Liver fibrosis in overweight patients.  Gastroenterology . 2000;  118 1117-1123
  CrossrefPubMedGoogle Scholar
• 5 Matteoni C A, Younossi Z M, Gramlich T. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology . 1999;  116 1413-1419
  CrossrefPubMedGoogle Scholar
• 6 Caldwell S H, Oelsner D H, Iezzoni J C. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying liver disease.  Hepatology . 1999;  29 664-669
  CrossrefPubMedGoogle Scholar
• 7 Marceau P, Biron S, Hould F-S. Liver pathology and the metabolic syndrome X in severe obesity.  J Clin Endocrinol Metab . 1999;  84 1513-1517
  CrossrefPubMedGoogle Scholar
• 8 Brunt E M. Nonalcoholic steatohepatitis: definition and pathology.  Semin Liver Dis . 2001;  21 3-16
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Brunt E M, Janney C G, Di Bisceglie M A. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.  Am J Gastroenterol . 1999;  94 2467-2474
  CrossrefPubMedGoogle Scholar
• 10 Chitturi S, Farrell G C. Drug-induced liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver, 9th ed Philadelphia: Lippincott Williams & Wilkins (in press)
  Google Scholar
• 11 Farrell G C. Drug-Induced Liver Disease.  Edinburgh: Churchill Livingstone 1994
  Google Scholar
• 12 Zimmerman H J. Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999
  Google Scholar
• 13 Farrell G C. Drugs and non-alcoholic steatohepatitis. In: Leuschner U, James O, Dancygier H, eds. Falk Symposium 121-Steatohepatitis (NASH and ASH) Dordrecht: Kluwer Academic Publishers 2000: 132-139
  Google Scholar
• 14 Marchesini G, Brizi M, Morselli-Labate A M. Association of nonalcoholic fatty liver disease with insulin resistance.  Am J Med . 1999;  107 450-455
  Google Scholar
• 15 Chitturi S, Abeygunasekera S, Farrell G C. NASH and insulin resistance: insulin hypersecretion, and specific association with the insulin resistance syndrome.  Hepatology . 2002;  35 373-379
  CrossrefPubMedGoogle Scholar
• 16 Chitturi S, Farrell G C. Etiopathogenesis of nonalcoholic steatohepatitis.  Semin Liver Dis . 2001;  21 27-42
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Cortez-Pinto H, Camilo M E, Baptista A. Non-alcoholic fatty liver: another feature of the metabolic syndrome?.  Clin Nutr . 1999;  18 353-358
  PubMedGoogle Scholar
• 18 Sanyal A J, Campbell-Sargent C, Mirshahi F. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.  Gastroenterology . 2001;  120 1183-1192
  CrossrefPubMedGoogle Scholar
• 19 Angulo P, Lindor K D. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue.  Gastroenterology . 2001;  120 1281-1285
  PubMedGoogle Scholar
• 20 Itoh S, Tsukada Y. Clinico-pathological and electron microscopical studies on a coronary dilating agent: 4,4′-diethylaminoethoxyhexestrol-induced liver injuries.  Acta Hepatogastroenterol (Stuttg) . 1973;  20 204-215
  PubMedGoogle Scholar
• 21 Paliard P, Vitrey D, Fournier G. Perhexiline maleate- induced hepatitis.  Digestion . 1978;  17 419-427
  PubMedGoogle Scholar
• 22 Pessayre D, Bichara M, Degott C. Perhexiline maleate- induced cirrhosis.  Gastroenterology . 1979;  76 170-177
  PubMedGoogle Scholar
• 23 Morgan M, Reshef R, Shah R R. Impaired oxidation of debrisoquine in patients with perhexiline liver injury.  Gut . 1984;  25 1057-1064
  CrossrefPubMedGoogle Scholar
• 24 Pirovino M, Müller O, Zysset T. Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model.  Hepatology . 1988;  8 591-598
  CrossrefPubMedGoogle Scholar
• 25 Lullman H, Lullman-Rauch R, Wasserman O. Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine.  CRC Crit Rev Toxicol . 1975;  4 185-218
  PubMedGoogle Scholar
• 26 Babany G, Uzzan F, Larrey D. Alcoholic-like liver lesions induced by nifedipine.  Hepatology . 1989;  9 252-255
  PubMedGoogle Scholar
• 27 Beaugrand M, Denis J, Callard P. Tous les inhibiteurs calciques peuvent-ils entrainer des lésions d'hépatite alcoolique?.  Gastroenterol Clin Biol . 1987;  1 76
  PubMedGoogle Scholar
• 28 Cortez-Pinto H, Baptista A, Camilo M E. Tamoxifen-associated steatohepatitis-report of three cases.  J Hepatol . 1995;  23 95-97
  CrossrefPubMedGoogle Scholar
• 29 Pratt D S, Knox T A, Erban J. Tamoxifen-induced steatohepatitis (letter).  Ann Intern Med . 1995;  123 236
  PubMedGoogle Scholar
• 30 Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced steatohepatitis (letter).  Ann Intern Med . 1996;  124 855-856
  PubMedGoogle Scholar
• 31 Oien K A, Moffat D, Curry G W. Cirrhosis with steatohepatitis after adjuvant tamoxifen (letter).  Lancet . 1999;  353 36-37
  CrossrefPubMedGoogle Scholar
• 32 Ogawa Y, Murata Y, Nishioka A. Tamoxifen-induced fatty liver in patients with breast cancer (letter).  Lancet . 1998;  351 725
  PubMedGoogle Scholar
• 33 Murata Y, Ogawa Y, Saibara T. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.  Oncol Rep . 2000;  7 1299-1304
  PubMedGoogle Scholar
• 34 Dray X, Tainturier M H, De La Lande P. Cirrhosis with nonalcoholic steatohepatitis: role of tamoxifen.  Gastroenterol Clin Biol . 2000;  24 1122-1123
  PubMedGoogle Scholar
• 35 Døssing M, Arlien-Søborg P, Milling Petersen L. Liver damage associated with occupational exposure to organic solvents in house painters.  Eur J Clin Invest . 1983;  13 151-157
  PubMedGoogle Scholar
• 36 Berson A, De Beco V, Letteron P. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes.  Gastroenterology . 1998;  114 764-774
  PubMedGoogle Scholar
• 37 Pessayre D, Mansouri A, Haouzi D. Hepatotoxicity due to mitochondrial dysfunction.  Cell Biol Toxicol . 1999;  15 367-373
  PubMedGoogle Scholar
• 38 Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis.  Semin Liver Dis . 2001;  21 57-70
  Article in Thieme ConnectPubMedGoogle Scholar
• 39 Tuquet C, Dupont J, Mesneau A. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria.  Cell Biol Toxicol . 2000;  16 207-219
  CrossrefPubMedGoogle Scholar
• 40 Fiatarone J R, Coverdale S A, Batey R G. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridaemia may be clues to its pathogenesis.  J Gastroenterol Hepatol . 1991;  6 585-590
  PubMedGoogle Scholar
• 41 Leclercq I A, Farrell G C, Field J. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis.  J Clin Invest . 2000;  105 1067-1075
  PubMedGoogle Scholar
• 42 Robertson G, Leclercq I, Farrell G C. Cytochrome P450 and oxidative stress.  Am J Physiol . 2001;  281 G1135-G1139
  PubMedGoogle Scholar
• 43 Rao M S, Reddy J K. Peroxisomal β-oxidation and steatohepatitis.  Semin Liver Dis . 2001;  21 43-56
  PubMedGoogle Scholar
• 44 Bedoucha M, Atzpodien E, Boelsterli U A. Diabetic KKA^y mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.  J Hepatol . 2001;  17 17-23
  PubMedGoogle Scholar
• 45 McKenzie R, Fried M W, Sallie R. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.  N Engl J Med . 1995;  333 1099-1105
  CrossrefPubMedGoogle Scholar
• 46 Sulkowski M S, Thomas D L, Chaisson R E, Moore R D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus.  JAMA . 2000;  283 74-80
  CrossrefPubMedGoogle Scholar
• 47 Brinkman K, ter Hofstede J M H, Burger D M. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway.  AIDS . 1998;  12 1735-1744
  PubMedGoogle Scholar
• 48 White A J. Mitochondrial toxicity and HIV therapy.  Sex Transm Infect . 2001;  77 159-173
  PubMedGoogle Scholar
• 49 McGovern B, Garan H, Kelly E, Ruskin J N. Adverse reactions during treatment with amiodarone hydrochloride.  Br Med J . 1983;  287 175-180
  PubMedGoogle Scholar
• 50 Fogoros R N, Anderson K P, Winkle R A. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias.  Circulation . 1983;  68 88-94
  PubMedGoogle Scholar
• 51 Waxman H L, Groh W C, Marchlinski F E. Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients.  Am J Cardiol . 1982;  50 1066-1074
  CrossrefPubMedGoogle Scholar
• 52 Mason J W. Amiodarone.  N Engl J Med . 1987;  316 455-466
  PubMedGoogle Scholar
• 53 Lewis J H, Ranard R C, Caruso A. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients.  Hepatology . 1989;  9 679-685
  CrossrefPubMedGoogle Scholar
• 54 Simon J B, Manley P N, Brien J F. Amiodarone hepatotoxicity simulating alcoholic liver disease.  N Engl J Med . 1984;  311 167-172
  PubMedGoogle Scholar
• 55 Lewis J H, Mullick F, Ishak K G. Histopathologic analysis of suspected amiodarone hepatotoxicity.  Hum Pathol . 1990;  21 59-67
  CrossrefPubMedGoogle Scholar
• 56 Gilinsky N H, Briscoe G W, Kuo C-S. Fatal amiodarone hepatotoxicity.  Am J Gastroenterol . 1988;  83 161-163
  PubMedGoogle Scholar
• 57 Rigas B. The evolving spectrum of amiodarone hepatotoxicity.  Hepatology . 1989;  10 116-117
  PubMedGoogle Scholar
• 58 Richer M, Roberts S. Fatal hepatotoxicity following oral administration of amiodarone.  Ann Pharmacother . 1995;  29 582
  PubMedGoogle Scholar
• 59 Chang C C, Petrelli M, Tomashefski J F. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature.  Arch Pathol Lab Med . 1999;  123 251-256
  PubMedGoogle Scholar
• 60 Beuers U, Heuck A. Images in hepatology. Iodine accumulation in the liver during long-term treatment with amiodarone.  J Hepatol . 1997;  26 439
  CrossrefPubMedGoogle Scholar
• 61 Hilleman D, Miller M A, Parker R. Optimal management of amiodarone therapy: efficacy and side effects.  Pharmacotherapy . 1998;  18 138S-145S
  PubMedGoogle Scholar
• 62 Hall P de la M. Histopathology of drug-induced liver disease. In: Farrell GC Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone 1994: 115-151
  Google Scholar
• 63 Moffat D F, Oien K A, Dickson J. Hepatocellular carcinoma after long-term tamoxifen therapy.  Ann Oncol . 2000;  11 1195-1196
  CrossrefPubMedGoogle Scholar
• 64 Smith L L, Brown K, Carthew P. Chemoprevention of breast cancer by tamoxifen: risks and opportunities.  Crit Rev Toxicol . 2000;  30 571-594
  PubMedGoogle Scholar
• 65 Storen E C, Hay J E, Kaur J. Tamoxifen-induced submassive hepatic necrosis.  Cancer J . 2000;  6 58-60
  PubMedGoogle Scholar
• 66 Saibara T, Ogawa Y, Takahashi M. Tamoxifen-induced nonalcoholic steatohepatitis and bezafibrate (abstract).  J Gastroenterol Hepatol . 2000;  15(Suppl) F96
  PubMedGoogle Scholar
• 67 Nguyen M C, Stewart R B, Banerji M A. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer.  Int J Obes Relat Metab Disord . 2001;  25 296-298
  CrossrefPubMedGoogle Scholar
• 68 Hamada N, Ogawa Y, Saibara T. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.  Int J Oncol . 2000;  17 1119
  PubMedGoogle Scholar
• 69 Seki K, Minami Y, Nishikawa M. Nonalcoholic steatohepatitis induced by massive doses of synthetic estrogen.  Gastroenterol Jpn . 1983;  18 197-203
  PubMedGoogle Scholar
• 70 Itoh S, Igarashi M, Tsukada Y. Nonalcoholic fatty liver with alcoholic hyaline after long-term glucocorticoid therapy.  Acta Hepatogastroenterol (Stuttg) . 1977;  24 415-418
  PubMedGoogle Scholar
• 71 Kumar K L, Colley C A. Verapamil-induced hepatotoxicity.  West J Med . 1994;  160 485-486
  PubMedGoogle Scholar
• 72 Kakuda T N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.  Clin Ther . 2000;  22 685-708
  CrossrefPubMedGoogle Scholar
• 73 Brinkman K, ter Hofstede J H. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options.  AIDS Rev . 1999;  1 140-146
  PubMedGoogle Scholar
• 74 Sundar K, Suarez M, Banogon P E. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature.  Crit Care Med . 1997;  25 1425-1430
  PubMedGoogle Scholar
• 75 Freiman J P, Helfert K E, Hamrell M R. Hepatomegaly with severe steatosis in HIV-seropositive patients.  AIDS . 1993;  7 379-385
  CrossrefPubMedGoogle Scholar
• 76 Chariot P, Drogou I, de Lacroix-Szmania I. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.  J Hepatol . 1999;  30 156-160
  CrossrefPubMedGoogle Scholar
• 77 Lai K K, Gang D L, Zawacki J K. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI).  Ann Intern Med . 1991;  115 283-284
  PubMedGoogle Scholar
• 78 Bissuel F, Bruneel F, Habersetzer F. Fulminant hepatitis with severe lactic acidosis in HIV-infected patients on didanosine therapy.  J Intern Med . 1994;  235 367-371
  CrossrefPubMedGoogle Scholar
• 79 John M, Moore C B, James I R. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.  AIDS . 2001;  15 717-723
  PubMedGoogle Scholar
• 80 Carr A, Cooper D A. Adverse effects of antiretroviral therapy.  Lancet . 2000;  356 1423-1430
  CrossrefPubMedGoogle Scholar
• 81 Flexner C. HIV-protease inhibitors.  N Engl J Med . 1998;  338 1281-1292
  CrossrefPubMedGoogle Scholar
• 82 Arribas J R, Ibanez C, Ruiz-Antoran B. Acute hepatitis in HIV-infected patients during ritonavir treatment.  AIDS . 1998;  12 1722-1724
  PubMedGoogle Scholar
• 83 Picard O, Rosmorduc O, Cabane J. Hepatotoxicity associated with ritonavir (letter).  Ann Intern Med . 1998;  129 670
  PubMedGoogle Scholar
• 84 Bräu N, Leaf H L, Wieczorek R L. Severe hepatitis in three AIDS patients treated with indinavir (letter).  Lancet . 1997;  349 924
  PubMedGoogle Scholar
• 85 Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide 1997-2000. JAMA.  2001;  285 402-403
  PubMedGoogle Scholar
• 86 Miller K D, Cameron M, Wood L V. Lactic acidosis hepatic steatosis associated with use of stavudine: report of four cases.  Ann Intern Med . 2000;  133 192-196
  PubMedGoogle Scholar
• 87 Bleeker-Rovers C P, Kadir S W, van Leusen R. Hepatic steatosis lacticacidosis caused by stavudine in an HIV-infected patient.  Neth J Med . 2000;  57 190-193
  PubMedGoogle Scholar
• 88 Roy P-M, Gouello J P, Pennison-Besnier I, Chennebault J M. Severe lactic acidosis induced by nucleoside analogues in an HIV-infected man.  Ann Emerg Med . 1999;  34 282-284
  PubMedGoogle Scholar
• 89 Whiting-O'Keefe Q E, Fyfe K H, Sack K D. Methotrexate histologic hepatic abnormalities: a meta-analysis.  Am J Med . 1991;  90 711-716
  PubMedGoogle Scholar
• 90 Hall P de la M, Langman G. The role of non-alcoholic steatohepatitis (NASH) in methotrexate-induced liver injury.  J Gastroenterol Hepatol (in press). 2000; 
  PubMedGoogle Scholar
• 91 Arranto A J, Sotaniemi E A. Morphologic alterations in patients with alpha-methyldopa-induced liver damage after short-long-termexposure.  Scand J Gastroenterol . 1981;  16 853-857
  PubMedGoogle Scholar
• 92 Grieco A, Alfei B, Di Rocco P. Non-alcoholic steatohepatitis induced by carbamazepine variegate porphyria.  Eur J Gastroenterol Hepatol . 2001;  13 973-975
  CrossrefPubMedGoogle Scholar
• 93 Redlich C A, West A B, Fleming L. Clinical pathologic characteristics associated with occupational exposure to dimethylformamide.  Gastroenterology . 1990;  99 748-757
  PubMedGoogle Scholar
• 94 Cotrim H P, Andrade Z A, Parana R. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers.  Liver . 1999;  19 299-304
  PubMedGoogle Scholar
• 95 Solis-Herruzo J A, Vidal J V, Colina F. Clinico-biochemical evolution late hepatic lesions in the toxic oil syndrome.  Gastroenterology . 1987;  93 558-568
  PubMedGoogle Scholar